Limula Announces Collaboration with Leading Cancer Centre to Improve Blood Products Processing for Stem Cell Transplantation
Limula and Institut Paoli-Calmettes teams together at the facility in Marseilles, France, alongside the installed and operational LimONE system.
- Limula partners with Institut Paoli-Calmettes (Marseille, France) to advance haematopoietic stem cell (HSC) processing for transplants.
- IPC will adopt LimONE to automate critical steps, including cryoprotectant removal prior to infusion, enhancing treatment quality and consistency.
- The collaboration highlights LimONE’s versatility and the potential to significantly improve cancer patient care.
Lausanne, Switzerland, September 15, 2025 – Limula, a Swiss life sciences tools company advancing automated solutions for cell and gene therapy (CGT) manufacturing today announced the collaboration with the Institut Paoli-Calmettes (IPC) to characterise the cell processing capabilities of LimONE for haematopoietic stem cell (HSC) transplantation applications.
IPC is internationally recognised as a leading treatment centre for cell therapies in haematological cancers and runs one of the most established autologous and allogeneic stem cell transplantation programmes in Europe. Performing more than 150 transplants each year, IPC is committed to advancing clinical innovation and broadening patient access to cutting-edge treatments.
The collaboration will leverage Limula’s automated and closed LimONE platform for autologous HSC transplantation, a procedure impacting nearly 50,000 patients annually in Europe. After promising preliminary results using an early prototype of Limula’s technology in 2022, and with strong confirmatory results earlier in 2025, IPC will further document the performance of LimONE. The goal of the collaboration is to advance automated cell product processing, with a focus on the removing of cryoprotectants and cell debris from thawed apheresis products. A fast and efficient wash is critical for maintaining the quality and consistency of the cell product and also significantly improves the patient experience.
“We are impressed with the improvements we saw during the development of LimONE and are eager to adopt the platform into our facility,” said Boris Calmels, Head of the Cellular Manufacturing Unit at IPC. “I see strong potential for Limula’s technology to play a key role in improving both our cell processes and the patient’s experience during stem cell transplantation.”
Luc Henry, CEO of Limula added: “This collaboration is a powerful demonstration of the versatility of our platform. We are proud to support IPC in their mission to deliver high-quality transplantation products to their patients.”
About Limula
Limula SA is a life science tools company based in Lausanne, Switzerland. Its mission is to accelerate the development and commercialization of advanced therapies through an automated, on-demand, and scalable manufacturing solution. Limula’s proprietary platform integrates the entire CGT workflow into a single device, empowering therapy developers to bring life-saving treatments to patients faster and more efficiently.
About Paoli-Calmettes Institute
Based in Marseilles, Paoli-Calmettes Institute is the first cancer comprehensive centre in region providing global care for cancer. It is a member of the national federation Unicancer. The Institute has been licensed by the HAS (the overall French health authority) at the highest level in 2021. The Centre gathers 2,000 employees – researchers, medical doctors, health and administrative staff – engaged in wide range of activities on site: prevention, research, treatment and training. IPC registered over 100,000 consultations and almost 11 000 new patients in 2024. In addition, over 400 researchers work in close collaboration with the medical teams to offer the cutting edge scientific advancements and the highest level treatments against cancers.
For more information visit www.institutpaolicalmettes.fr
Contact Details
Luc Henry, DPhil
media@limula.ch
www.limula.ch